Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Aroxxen

Phase 2Small molecule

RResearch Institute of Geroprotective Technologies

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stent ImplantationNot yet recruiting

Stent ImplantationPhase 2

Not yet recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Stent Implantation

NCT07397351

Clinical

Trials by Indication[1]

Stent Implantation1 trial

Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation

Not yet recruiting·RResearch Institute of Geroprotective Technologies·Phase 2·NCT07397351·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Aroxxen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aroxxen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aroxxen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Research Institute of Geroprotective Technologies company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RResearch Institute of Geroprotective Technologies

Related News